Stock Events

Stock Events

Geron 

$1.54
132
+$0.17+12.41% Monday 21:00

Statistics

Day High
1.58
Day Low
1.35
52W High
3.09
52W Low
1.04
Volume
27,138,733
Avg. Volume
8,961,544
Mkt Cap
983.07M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.1
-0.08
-0.05
-0.02
Expected EPS
-0.031667
Actual EPS
N/A

Financials

-226.73%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
153.99MRevenue
-349.14MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GERN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology company focused on developing novel therapies, including for hematologic malignancies, which competes with Geron's focus on blood cancers.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for various cancers, directly competing with Geron's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers a wide range of cancer treatments, including those for hematologic cancers, making it a direct competitor to Geron.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company with a significant presence in oncology, including research in treatments for blood cancers, competing with Geron's development focus.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse oncology portfolio, including therapies for breast and hematologic cancers, positioning it as a competitor to Geron.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, with its acquisition of Pharmacyclics, has expanded its oncology portfolio, including treatments for hematologic malignancies, competing with Geron's therapeutic area.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in cell therapies for cancer, including hematologic malignancies, competing with Geron's focus.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is involved in the development of cancer treatments, including immunotherapies that could be used in treating hematologic cancers, making it a competitor to Geron.
Rogers
ROG
Mkt Cap1.57B
Roche, with its strong focus on oncology and a broad portfolio of cancer treatments, including for blood cancers, competes with Geron in the oncology space.

About

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Show more...
CEO
Ms. Michelle J. Robertson
Employees
229
Country
US
ISIN
US3741631036

Listings

MI
IT
1GERN.MI
LSE
GB
0IV3.LSE
BOATS
BOATS
GERN.BOATS
F
DE
GON.F

0 Comments

Share your thoughts

FAQ

What is Geron stock price today?▼
The current price of GERN is $1.54 USD — it has increased by +12.41% in the past 24 hours. Watch Geron stock price performance more closely on the chart.
What is Geron stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Geron stocks are traded under the ticker GERN.
Is Geron stock price growing?▼
GERN stock has risen by +11.59% compared to the previous week, the month change is a +16.67% rise, over the last year Geron has showed a -45.96% decrease.
What is Geron market cap?▼
Today Geron has the market capitalization of 983.07M
When is the next Geron earnings date?▼
Geron is going to release the next earnings report on March 12, 2026.
What were Geron earnings last quarter?▼
GERN earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.03 USD resulting in a +5.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Geron revenue for the last year?▼
Geron revenue for the last year amounts to 153.99M USD.
What is Geron net income for the last year?▼
GERN net income for the last year is -349.14M USD.
How many employees does Geron have?▼
As of February 03, 2026, the company has 229 employees.
In which sector is Geron located?▼
Geron operates in the Health Care sector.
When did Geron complete a stock split?▼
Geron has not had any recent stock splits.
Where is Geron headquartered?▼
Geron is headquartered in Foster City, US.